Conversations in Drug Development Trends

OCTOBER 29, 2024

Increasingly, patients and patient-led organizations are playing a pivotal role in shaping drug development, underscoring the importance of collaboration between patient organizations, CROs, and pharmaceutical and biotechnology companies. Discover more about this industry shift in our blog.

Clinical Research 72

Clinical Research Disease Research Clinical Trials 72

Drug & Device Law

MARCH 4, 2024

Plaintiffs will not be heard to argue that they “could have shored up their cases by other means had they known their expert testimony would be found inadmissible.” His inability to produce admissible expert testimony is due to his own actions, namely the failure of his proposed experts to test their alternatives. Weisgram v.

Testimonials 52

Testimonials Production Vaccine Pharmaceuticals 52

Drug & Device Law

FEBRUARY 11, 2024

We’ve blogged several times already about the Alliance for Hippocratic Medicine v. Congress created an FDA approval process that is both rigorous and thorough, and pharmaceutical companies invest billions of dollars in research and development to meet FDA’s scientific standards. FDA litigation that is now before the Supreme Court.

FDA 59

FDA Production FDA Approval Regulations 59

Drug & Device Law

JANUARY 5, 2024

I am Susanna Moldoveanu , and I practice with Butler Snow LLP’s Pharmaceutical, Medical Device and Healthcare group. I am excited to join the Drug & Device Law Blogging Team. A more fulsome discussion of the Washington Supreme Court’s answer is on the Blog. Plaintiffs had no evidence to rebut the treater’s clear testimony.

Testimonials 52

Testimonials Production Doctors Pharmaceuticals 52

Drug & Device Law

DECEMBER 29, 2023

2023) (remote trial testimony cannot be compelled beyond Rule 45’s 100-mile limit on subpoenas) ( here ); Carson v. 2023) (HHS cannot force pharmaceutical manufacturers to sell unlimited amounts of prescription drugs at a discount) ( here ). They excluded bogus expert testimony under Fed. Bonta , 85 F.4th 4th 1263 (9th Cir.

Testimonials 105

Testimonials FDA Drugs Vaccine 105

Drug & Device Law

DECEMBER 26, 2023

As readers of the Blog undoubtedly know , the amendments toughening up Fed. Testimony by expert witnesses. But it remains the case that other admissibility requirements in the rule (such as that the expert must be qualified and the expert’s testimony must help the trier of fact) are governed by the Rule 104(a) standard as well.

Testimonials 52

Testimonials Government Production Pharmaceuticals 52

Drug & Device Law

AUGUST 2, 2023

It had filed an amicus brief with the Second Circuit and its post-decision press release headline was “In WLF Success, Second Circuit Affirms Exclusion of an unreliable Causation Evidence in Pharmaceutical Case.” In addition, we blogged about the district court order here. Plus, the case involves some lawyers we know and respect.

Science 52

Science Testimonials Compliance Pharmaceuticals 52